In this webinar, we took a deep dive into the increasingly evolving landscape, and explored the dynamics surrounding PROTACS, emerging bivalent degrader targets, and the spectrum of cancer and non-cancer indications. We examined the trajectory of this field amidst the influx of investments, shedding light on its evolution and potential future directions. Watch the recording now.
Speak with our team about Beacon TPD
What is Beacon TPD?
Beacon TPD covers trial and drug records for clinical,
preclinical, approved and discontinued therapeutics
involved in targeted protein degradation and induced
proximity. The database covers:
- Bivalent Degraders
- Monovalent Degraders
- Induced Proximity Assets
- Proteasome Inhibitors
- DUB Inhibitors
- E1/E2/E3 Modulators
- Other comparable modalities
New data expansion: Deals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading the factsheet.
How Beacon TPD Works
Search the trial and drug landscape by target, ligands and effectors alongside
other search criteria to instantly extract
the data points you need to conduct
more complex analysis.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the TPD space.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
